ArticleAdvances in patient-reported outcomes2025
Validity evidence for the Patient Reported Outcome Measurement Information System (PROMIS)
Article in Advances in patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objectives: This study aims to provide evidence on the validity of the Patient Reported Outcome Measurement Information System (PROMIS) Methods: We analyzed data of 19,037 patients aged 65+ who completed the cognitive screener during their Medicare Annual Wellness visit (Once=16,115; Twice= 2922) in a large healthcare system. Bivariate and multivariate ordinary least squares and logistic regression were used to examine key risk factors and their cross-sectional and predictive relationships with PRO-CS scores and cognitive decline. Results: We found cognitive impairment based on PRO-CS scores was associated with having a clinical diagnosis (unadjusted Odds Ratio = -3.22(0.18), p < .001). PRO-CS scores were also found to have cross-sectional relationships with a wide range of known risk factors for cognitive impairment, including age, emotional distress, social needs, frailty, and overall general health (all ps < .001). Group-level analyses indicate that PRO-CS scores were useful for detecting subjective cognitive decline occurring within one year, with declining scores predicted by indicators of frailty and general health (all ps < .001). Conclusion: Our findings support the validity of using the PRO-CS to detect risk for subjective cognitive decline among older adults during Medicare Annual Wellness visits. Specifically, the PRO-CS is useful in detecting potential cases of MCI and subjective cognitive decline who are at higher risk of transitioning into a confirmed diagnosis of MCI or dementia in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.